Editorial: The safety and efficacy of ustekinumab in anti-TNF α refractory pediatric inflammatory bowel disease.
作者信息
Ho Katelynn K, Suskind David L, Wahbeh Ghassan T
机构信息
Pediatric Gastroenterology, Hepatology and Nutrition, Seattle Children's Hospital - University of Washington, Seattle, WA, United States.
出版信息
Saudi J Gastroenterol. 2025 Mar 1;31(2):51-52. doi: 10.4103/sjg.sjg_384_24. Epub 2025 Mar 12.
Abstract
摘要
相似文献
1
Editorial: The safety and efficacy of ustekinumab in anti-TNF α refractory pediatric inflammatory bowel disease.
Saudi J Gastroenterol. 2025 Mar 1;31(2):51-52. doi: 10.4103/sjg.sjg_384_24. Epub 2025 Mar 12.
2
Augmented ustekinumab dosing is needed to achieve clinical response in patients with anti-TNF refractory pediatric Crohn's disease: a retrospective chart review.
F1000Res. 2020 Apr 30;9:316. doi: 10.12688/f1000research.22673.2. eCollection 2020.
3
Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):763-770. doi: 10.1097/MPG.0000000000003758. Epub 2023 Mar 8.
4
Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2025 Jan;23(1):144-153.e22. doi: 10.1016/j.cgh.2023.12.029. Epub 2024 Jan 8.
5
Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
J Comp Eff Res. 2017 Oct;6(7):601-612. doi: 10.2217/cer-2017-0022. Epub 2017 Jun 29.
6
Ustekinumab for children and adolescents with inflammatory bowel disease at a tertiary children's hospital in Japan.
J Gastroenterol Hepatol. 2021 Jan;36(1):125-130. doi: 10.1111/jgh.15128. Epub 2020 Jun 29.
7
Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: a nationwide population-based cohort study.
Therap Adv Gastroenterol. 2024 Jul 31;17:17562848241265013. doi: 10.1177/17562848241265013. eCollection 2024.
8
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30.
9
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
J Clin Med. 2024 Apr 10;13(8):2187. doi: 10.3390/jcm13082187.
10
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
BMC Gastroenterol. 2022 Nov 17;22(1):464. doi: 10.1186/s12876-022-02559-5.
本文引用的文献
1
Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease.
J Pediatr Gastroenterol Nutr. 2024 Jul;79(1):62-75. doi: 10.1002/jpn3.12221. Epub 2024 May 2.
2
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study.
Saudi J Gastroenterol. 2025 Mar 1;31(2):59-67. doi: 10.4103/sjg.sjg_7_24. Epub 2024 Apr 10.
3
Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report.
Medicina (Kaunas). 2024 Jan 6;60(1):106. doi: 10.3390/medicina60010106.
4
Ustekinumab Use in Pediatric Inflammatory Bowel Disease: A French Multicenter Study From the Pediatric GETAID.
J Pediatr Gastroenterol Nutr. 2023 Jun 1;76(6):763-770. doi: 10.1097/MPG.0000000000003758. Epub 2023 Mar 8.
5
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):616-627. doi: 10.1016/S2468-1253(21)00142-4. Epub 2021 Jun 19.
6
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
J Crohns Colitis. 2021 Nov 8;15(11):1931-1942. doi: 10.1093/ecco-jcc/jjab089.
7
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
8
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
J Pediatr Gastroenterol Nutr. 2019 Jul;69(1):61-67. doi: 10.1097/MPG.0000000000002362.
9
Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
J Crohns Colitis. 2019 Apr 26;13(5):578-584. doi: 10.1093/ecco-jcc/jjy206.
10
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773.
Zotero 插件